[Pindolol in pediatrics. Evaluation of cardiac haemodinamics (author's transl)]

Insights

This study explored the effects of the beta-blocking agent Pindolol in children, finding significant variations in certain cardiac parameters but not heart rate or blood pressure. The drug demonstrated easy pediatric utilization.

Area of Science:

  • Pediatric pharmacology
  • Cardiovascular research
  • Clinical drug evaluation

Context:

  • Limited research exists on beta-blocking agents' effects in pediatric populations.
  • Pindolol (Visken Sandoz), a beta-blocking agent, was studied in children.
  • Previous studies focused primarily on adult responses to beta-blockers.

Purpose:

  • To investigate the pharmacological effects of a beta-blocking agent (Pindolol) in healthy children.
  • To assess changes in cardiovascular parameters following a 10-day therapeutic cycle of Pindolol.
  • To evaluate the safety and usability of Pindolol for pediatric use.

Summary:

  • Nineteen healthy children (5-13 years) received Pindolol (250 gamma/kg/day) for 10 days.
  • Significant variations were observed in TD, TT, TT/TET, and QTc intervals.
  • No significant changes were noted in heart rate, TET, SM, QA2, diastolic parameters, or arterial blood pressure.

Impact:

  • Suggests potential chronotropic and hypotensive effects in pediatric patients with pre-existing cardiac rate or blood pressure alterations.
  • Highlights the easy administration and utilization of Pindolol in pediatric settings.
  • Provides foundational data for further pediatric research on beta-blocking agents.